Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has launched Benefix with Room Temperature Storage (RTS) in Europe to treat haemophilia B, following its approval by the European Commission.
Subscribe to our email newsletter
Benefix RTS can be stored for up to two years at room temperature (2-30°C) for about two years, thereby providing more convenience to haemophilia B patients, europeanpharmaceuticalreview reported.
Benefix is a recombinant factor IX (rFIX) product licensed for the treatment and prophylaxis of bleeding in patients with haemophilia B.
The product is said to be free from the risk of transmission of human blood-borne pathogens.
Pfizer regional resident Europe Cees Heiman said the treatment has transformed the outlook for haemophilia B patients over a decade ago.